Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2019)

Posted by Matt Breese on Apr 5, 2019

Find me on:

According to our recent payer coverage analysis for acute myeloid leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for acute myeloid leukemia treatments shows that under the pharmacy benefit, almost 60% of the lives under commercial formularies are covered with utilization management restrictions. 

MMIT-Reality Check-AML_1Q2019Data snapshot as of Q1 2019

Trends: With the FDA approving multiple novel new therapies over the past couple of years, more of the same is expected in 2019. In the oncology space, one expert says she is keeping an eye on quizartinib from Ambit Biosciences. Via AIS Health.

To read the full Reality Check on Acute Myeloid Leukemia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing